Takei, G
Mukherjee A, Malik H, Saha AP, Dubey A, Singhal DK, Boateng S, Saugandhika S, Kumar S, De S, Guha SK, Malakar D
FDA-Approved Versions and Supply Shortages The demand for Semaglutide for weight loss and diabetes management has skyrocketed, leading to shortages of FDA-approved versions of the medication
As of August 2026, there were 86 cases pending in MDL-3163
According to FDAs recommended method for removing duplicate reports, the PRIMARYID, CASEID, and FDA_DT fields of the DEMO table were selected and sorted in the order of CASEID, FDA_DT, and PRIMARYID, and for reports with the same CASEID, the one with the largest FDA_DT value was retained
Resuming a dose that is no longer well tolerated may increase the likelihood of gastrointestinal adverse effects such as nausea, vomiting and diarrhoea